This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...
Investing3d
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential
TERN-601, an oral GLP-1 receptor agonist for obesity, has also shown promise in early clinical trials. The Phase 1 study results revealed: A 4.9% placebo-adjusted weight loss over 28 days at the ...
Investing3d
Terns Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential
TERN-601, an oral GLP-1 receptor agonist for obesity, has also shown promise in early clinical trials. The Phase 1 study results revealed: A 4.9% placebo-adjusted weight loss over 28 days at the ...
Yahoo Finance6d
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Its two leading candidates, TERN-601 and TERN-501 -- both in the anti-obesity field -- are close to entering phase 2 studies. The stock's returns in the next few years will depend on clinical and ...